Still no harm reduction? A critical review of the UK Government’s new 2017 Drug Strategy

A briefing from the English Harm Reduction Group looks at whether the focus on harm reduction has improved under the new strategy, and discusses challenges in the funding environment which will have a disproportionate impact on harm reduction services. The briefing was also published by the EHRG as a letter in the British Medical Journal.

Read it here

Related Content